Table 2.

Genotypes for genetic polymorphisms in p53 and p21 and their effects on risk of CBP

GenotypeCases (%)*Controls (%)*OR (95% CI)ORadj. (95% CI)
P53 intron 3
    WW280 (94.6)258 (92.8)1.001.00
    WM16 (5.4)20 (7.2)0.74 (0.37-1.45)% (0.22-1.58)
    MM0 (0.00)0 (0.0)
    WM+MM16 (5.4)20 (7.2)0.74 (0.37-1.47)% (0.22-1.58)
P53 C119G
    CC56 (18.7)51 (17.8)1.001.00
    CG144 (48.0)142 (49.5)0.92 (0.59-1.44)1.04 (0.58-1.87)
    GG100 (33.3)94 (32.8)0.97 (0.60-1.55)0.87 (0.46-1.63)
    CG+GG244 (81.3)236 (82.2)0.94 (0.62-1.43)0.97 (0.55-1.69)
P53 IVS6+62 G>A
    GG272 (89.8)265 (90.1)1.001.00
    GA31 (10.2)29 (9.9)1.04 (0.61-1.78)1.28 (0.63-2.57)
    AA0 (0.00)0 (0.0)
    GA+AA31 (10.2)29 (9.9)1.04 (0.61-1.78)1.28 (0.63-2.57)
P21 C98A
    CC100 (33.0)65 (22.5)1.001.00
    CA158 (52.2)173 (59.9)0.59 (0.41-0.87)§0.48 (0.29-0.79)§
    AA45 (14.9)51 (17.6)0.57 (0.35-0.95)0.67 (0.33-1.35)
    CA+AA203 (67.0)224 (77.5)0.59 (0.41-0.85)§0.51 (0.32-0.83)§
P21 C70T
    CC66 (21.9)45 (15.4)1.001.00
    CT104 (34.6)107 (36.6)0.66 (0.42-1.06)0.56 (0.29-1.06)
    TT131 (43.5)140 (48.0)0.64 (0.41-1.00)0.51 (0.28-0.94)
    CT+TT235 (78.1)247 (84.6)0.65 (0.43-0.99)0.53 (0.29-0.95)
  • * Data missing due to failure in DNA amplification.

  • ORs were adjusted for potential confounders including gender, cigarette smoking, alcohol consumption, exposure duration, and intensity of benzene exposure.

  • WW, wild-type homozygous; WM, wild-type/mutant heterozygous; MM, mutant homozygous.

  • § P < 0.01.

  • P < 0.05.